Pfizer’s CEO has been rapped by the U.K.’s pharmaceutical watchdog for making “misleading” statements about children’s vaccines. The Telegraph has the story.
Dr Albert Bourla used an interview with the BBC last December to claim that “there is no doubt in my mind that the benefits, completely, are in favour of” vaccinating youngsters aged five to 11 against COVID-19.
He argued that “Covid in schools is thriving” adding: “This is disturbing, significantly, the educational system, and there are kids that will have severe symptoms.”
The interview was published on December 2nd – before the vaccine had been approved by Britain’s medical regulator for this age group.
Shortly after the article’s publication, a complaint was submitted to the pharmaceutical watchdog – the Prescription Medicines Code of Practice Authority (PMCPA) – by UsForThem, a parent campaign group which was set up to promote the plight of children during the pandemic.
The complaint alleged that Dr. Bourla’s remarks about the children’s vaccine were “disgracefully misleading” and “extremely promotional in nature”, arguing that it breached several clauses of the Association of the British Pharmaceutical Industry’s (ABPI) code of practice.
“There is simply no evidence that healthy schoolchildren in the U.K. are at significant risk from the SARS-CoV-2 virus and to imply that they are is disgracefully misleading,” they said.
In September 2021, the Joint Committee on Vaccination and Immunisation (JCVI), had advised against a mass roll-out for children aged 12-15, saying the “margin of benefit” was “considered too small” and citing the low risk to healthy children from the virus.
But less than a fortnight later, ministers gave the green light for youngsters to be given a single dose of the Pfizer-BioNTech jab with the U.K.’s Chief Medical Officers arguing that this would help to keep schools open.
It was not until February 2022 that the JCVI ruled that children aged 5-11 could be offered the vaccine – but ministers said the decision should be left up to parents.